207 related articles for article (PubMed ID: 23642346)
1. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis.
Sørensen HJ; Jensen SO; Nielsen J
Eur Neuropsychopharmacol; 2013 Aug; 23(8):872-8. PubMed ID: 23642346
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case-control study.
Wu CS; Chang CM; Tsai YT; Huang YW; Tsai HJ
J Clin Psychiatry; 2015 Sep; 76(9):1216-23. PubMed ID: 26115407
[TBL] [Abstract][Full Text] [Related]
4. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway.
Bakken MS; Schjøtt J; Engeland A; Engesaeter LB; Ruths S
J Am Geriatr Soc; 2016 Jun; 64(6):1203-9. PubMed ID: 27321599
[TBL] [Abstract][Full Text] [Related]
6. Risk of hip fracture in patients with a history of schizophrenia.
Howard L; Kirkwood G; Leese M
Br J Psychiatry; 2007 Feb; 190():129-34. PubMed ID: 17267929
[TBL] [Abstract][Full Text] [Related]
7. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs.
Oderda LH; Young JR; Asche CV; Pepper GA
Ann Pharmacother; 2012; 46(7-8):917-28. PubMed ID: 22811347
[TBL] [Abstract][Full Text] [Related]
8. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
9. Hip fracture and antipsychotics.
Ang G; Pridmore S
Aust N Z J Psychiatry; 2007 Nov; 41(11):939-40. PubMed ID: 18074623
[No Abstract] [Full Text] [Related]
10. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland.
Solmi M; Lähteenvuo M; Correll CU; Tanskanen A; Tiihonen J; Taipale H
Schizophr Bull; 2023 Jan; 49(1):78-89. PubMed ID: 36334051
[TBL] [Abstract][Full Text] [Related]
11. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
12. The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
Shen SP; Liu Y; Qiu H; Tsai KY; Wu HC; Liang WM; Shu M; Chou FH
PLoS One; 2019; 14(9):e0221948. PubMed ID: 31487309
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease.
Koponen M; Taipale H; Lavikainen P; Tanskanen A; Tiihonen J; Tolppanen AM; Ahonen R; Hartikainen S
J Clin Psychiatry; 2017 Mar; 78(3):e257-e263. PubMed ID: 28146612
[TBL] [Abstract][Full Text] [Related]
14. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009.
Yoshio T; Inada T; Uno J; Miwa T; Kitagawa K; Miyahara Y; Umeda K; Kato T; Inagaki A; Nabeshima T
Hum Psychopharmacol; 2012 Jan; 27(1):70-5. PubMed ID: 22249957
[TBL] [Abstract][Full Text] [Related]
15. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
16. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia.
Fujita J; Nishida A; Sakata M; Noda T; Ito H
Psychiatry Clin Neurosci; 2013 Jul; 67(5):345-51. PubMed ID: 23711166
[TBL] [Abstract][Full Text] [Related]
17. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
18. Fracture risk from psychotropic medications: a population-based analysis.
Bolton JM; Metge C; Lix L; Prior H; Sareen J; Leslie WD
J Clin Psychopharmacol; 2008 Aug; 28(4):384-91. PubMed ID: 18626264
[TBL] [Abstract][Full Text] [Related]
19. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database.
Pratt N; Roughead EE; Ramsay E; Salter A; Ryan P
Drug Saf; 2011 Jul; 34(7):567-75. PubMed ID: 21663332
[TBL] [Abstract][Full Text] [Related]
20. [The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group].
Yoshio T
Seishin Shinkeigaku Zasshi; 2012; 114(6):690-5. PubMed ID: 22844820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
